PMID- 33123479
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201031
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Therapeutic Potential of Autophagy in Glioblastoma Treatment With 
      Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin 
      Signaling Pathway Inhibitors.
PG  - 572904
LID - 10.3389/fonc.2020.572904 [doi]
LID - 572904
AB  - Glioblastoma (GB) is the most malignant and aggressive form of brain tumor, 
      characterized by frequent hyperactivation of the phosphoinositide 3-kinase 
      (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling 
      pathway. PI3K/AKT/mTOR inhibitors have a promising clinical efficacy 
      theoretically. However, strong drug resistance is developed in GB against the 
      PI3K/AKT/mTOR inhibitors due to the cytoprotective effect and the adaptive 
      response of autophagy during the treatment of GB. Activation of autophagy by the 
      PI3K/AKT/mTOR inhibitors not only enhances treatment sensitivity but also leads 
      to cell survival when drug resistance develops in cancer cells. In this review, 
      we analyze how to increase the antitumor effect of the PI3K/AKT/mTOR inhibitors 
      in GB treatment, which is achieved by various mechanisms, among which targeting 
      autophagy is an important mechanism. We review the dual role of autophagy in both 
      GB therapy and resistance against inhibitors of the PI3K/AKT/mTOR signaling 
      pathway, and further discuss the possibility of using combinations of autophagy 
      and PI3K/AKT/mTOR inhibitors to improve the treatment efficacy for GB. Finally, 
      we provide new perspectives for targeting autophagy in GB therapy.
CI  - Copyright (c) 2020 Xia, Xu, Zhang, Liu, Meng and Dong.
FAU - Xia, Qin
AU  - Xia Q
AD  - School of Life Science, Beijing Institute of Technology, Beijing, China.
FAU - Xu, Mengchuan
AU  - Xu M
AD  - School of Life Science, Beijing Institute of Technology, Beijing, China.
FAU - Zhang, Pei
AU  - Zhang P
AD  - School of Life Science, Beijing Institute of Technology, Beijing, China.
FAU - Liu, Liqun
AU  - Liu L
AD  - School of Life Science, Beijing Institute of Technology, Beijing, China.
FAU - Meng, Xinyi
AU  - Meng X
AD  - School of Life Science, Beijing Institute of Technology, Beijing, China.
FAU - Dong, Lei
AU  - Dong L
AD  - School of Life Science, Beijing Institute of Technology, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201002
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7567033
OTO - NOTNLM
OT  - PI3K/AKT/mTOR inhibitors
OT  - autophagy
OT  - combination therapy
OT  - drug resistance
OT  - glioblastoma
EDAT- 2020/10/31 06:00
MHDA- 2020/10/31 06:01
PMCR- 2020/01/01
CRDT- 2020/10/30 05:55
PHST- 2020/06/15 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/10/30 05:55 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/10/31 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.572904 [doi]
PST - epublish
SO  - Front Oncol. 2020 Oct 2;10:572904. doi: 10.3389/fonc.2020.572904. eCollection 
      2020.